GCT 1046-06: A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

Objective

Clinical Trial Details

Principal Investigator(s)
Benjamin Solomon, MD

Clinical Trial Categories

  • Cancer
  • Lung Cancer
Contact
Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org

Location

  • Avera Cancer Institute — Mitchell
    605 N Foster St
    Mitchell, SD 57301
    Main: 605-995-5756
  • Avera Cancer Institute — Yankton
    1115 W 9th St
    Yankton, SD 57078
    Main: 605-668-8850
  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000
  • Avera Cancer Institute — Aberdeen
    310 S Penn St
    Suite 106
    Aberdeen, SD 57401
    Main: 605-622-8700
  • Avera Cancer Institute — Pierre
    801 E Sioux Ave
    Pierre, SD 57501
    Main: 605-224-3370